78 related articles for article (PubMed ID: 35093266)
1. Process and strategies for patient engagement and outreach in the Sickle Cell Disease (SCD) community to promote clinical trial participation.
Byrnes C; Botello-Harbaum M; Clemons T; Bailey L; Valdes KM; Coleman-Cowger VH
J Natl Med Assoc; 2022 Apr; 114(2):211-217. PubMed ID: 35093266
[TBL] [Abstract][Full Text] [Related]
2. The Meaning of Informed Consent: Genome Editing Clinical Trials for Sickle Cell Disease.
Desine S; Hollister BM; Abdallah KE; Persaud A; Hull SC; Bonham VL
AJOB Empir Bioeth; 2020; 11(4):195-207. PubMed ID: 33044907
[TBL] [Abstract][Full Text] [Related]
3. Developing an Implementation Blueprint for the NIH HEAL Initiative GRACE Trial: Perspectives on Acupuncture and Guided Relaxation for Chronic Sickle Cell Disease Pain.
Knisely MR; Rivera E; deMartelly VA; Abdulkadir A; Doorenbos AZ; Ezenwa MO; Molokie RE; Li H; Shah N; Schlaeger JM; Patil CL
J Integr Complement Med; 2023 Oct; 29(10):683-688. PubMed ID: 37184905
[No Abstract] [Full Text] [Related]
4. Effects of Experienced Discrimination in Pediatric Sickle Cell Disease: Caregiver and Provider Perspectives.
Blakey AO; Lavarin C; Brochier A; Amaro CM; Eilenberg JS; Kavanagh PL; Garg A; Drainoni ML; Long KA
J Racial Ethn Health Disparities; 2023 Dec; 10(6):3095-3106. PubMed ID: 36536165
[TBL] [Abstract][Full Text] [Related]
5. New ASH initiatives to improve patient care in the long-overlooked sickle cell disease.
Tubman VN; Mohandas N; Abrams CS
Blood; 2023 Jul; 142(3):230-234. PubMed ID: 37216689
[TBL] [Abstract][Full Text] [Related]
6. Current and Future Therapeutics for Treating Patients with Sickle Cell Disease.
Barak M; Hu C; Matthews A; Fortenberry YM
Cells; 2024 May; 13(10):. PubMed ID: 38786070
[TBL] [Abstract][Full Text] [Related]
7. Sickle cell disease: embedding patient participation into an international conference can transform the role of lived experience.
Pellegrini M; Chakravorty S; Del Mar Manu Pereira M; Gulbis B; Gilmour-Hamilton C; Hayes S; de Montalembert M; Inusa BPD; Colombatti R; Roy NB
Orphanet J Rare Dis; 2023 Nov; 18(1):341. PubMed ID: 37908000
[TBL] [Abstract][Full Text] [Related]
8. A Mixed-Methods Evaluation of a Project ECHO Program for the Evidence-Based Management of Sickle Cell Disease.
Mosley C; Farrell CB; Quinn CT; Shook LM
Int J Environ Res Public Health; 2024 Apr; 21(5):. PubMed ID: 38791745
[TBL] [Abstract][Full Text] [Related]
9. Looking ahead: ethical and social challenges of somatic gene therapy for sickle cell disease in Africa.
Munung NS; Nnodu OE; Moru PO; Kalu AA; Impouma B; Treadwell MJ; Wonkam A
Gene Ther; 2024 May; 31(5-6):202-208. PubMed ID: 38012299
[TBL] [Abstract][Full Text] [Related]
10. Publication of data collection forms from NHLBI funded sickle cell disease implementation consortium (SCDIC) registry.
Glassberg JA; Linton EA; Burson K; Hendershot T; Telfair J; Kanter J; Gordeuk VR; King AA; Melvin CL; Shah N; Hankins JS; Epié AY; Richardson LD;
Orphanet J Rare Dis; 2020 Jul; 15(1):178. PubMed ID: 32635939
[TBL] [Abstract][Full Text] [Related]
11. End points for sickle cell disease clinical trials: patient-reported outcomes, pain, and the brain.
Farrell AT; Panepinto J; Carroll CP; Darbari DS; Desai AA; King AA; Adams RJ; Barber TD; Brandow AM; DeBaun MR; Donahue MJ; Gupta K; Hankins JS; Kameka M; Kirkham FJ; Luksenburg H; Miller S; Oneal PA; Rees DC; Setse R; Sheehan VA; Strouse J; Stucky CL; Werner EM; Wood JC; Zempsky WT
Blood Adv; 2019 Dec; 3(23):3982-4001. PubMed ID: 31809538
[TBL] [Abstract][Full Text] [Related]
12. Management of Older Adults with Sickle Cell Disease: Considerations for Current and Emerging Therapies.
Oyedeji CI; Hodulik KL; Telen MJ; Strouse JJ
Drugs Aging; 2023 Apr; 40(4):317-334. PubMed ID: 36853587
[TBL] [Abstract][Full Text] [Related]
13. Development of a Hematology-General Medicine Hybrid Team to Improve Care of Patients With Sickle Cell Disease.
Merz LE; Osei MA; Green A; Story CM; Schuering KM; Achebe MO
Acad Med; 2024 Jun; 99(6):618-622. PubMed ID: 38412482
[TBL] [Abstract][Full Text] [Related]
14. The Rules of Engagement: CTTI Recommendations for Successful Collaborations Between Sponsors and Patient Groups Around Clinical Trials.
Bloom D; Beetsch J; Harker M; Hesterlee S; Moreira P; Patrick-Lake B; Selig W; Sherman J; Smith SK; Valentine JE; Roberts JN
Ther Innov Regul Sci; 2018 Mar; 52(2):206-213. PubMed ID: 29714514
[TBL] [Abstract][Full Text] [Related]
15. Contested Disability: Sickle Cell Disease.
Srikanthan S
Health Soc Work; 2023 Jul; 48(3):209-216. PubMed ID: 37315205
[TBL] [Abstract][Full Text] [Related]
16. The Bias of Medicine in Sickle Cell Disease.
Anderson D; Lien K; Agwu C; Ang PS; Abou Baker N
J Gen Intern Med; 2023 Nov; 38(14):3247-3251. PubMed ID: 37698721
[TBL] [Abstract][Full Text] [Related]
17. Views of adults living with sickle cell disease on the theoretical return of secondary genomic findings.
Floyd KJ; Wossenseged F; Buscetta AJ; Fasaye GA; Bonham VL
Genet Med; 2024 Jan; 26(1):100993. PubMed ID: 37811899
[TBL] [Abstract][Full Text] [Related]
18. [Transition in sickle cell disease - recommendations of the transition initiative sickle cell disease].
Böll J; Alashkar F; Aramayo-Singelmann C; Hoferer A; Jarisch A; Kamal H; Oevermann L; Schwarz M; Cario H
Dtsch Med Wochenschr; 2024 May; 149(10):579-586. PubMed ID: 38657597
[TBL] [Abstract][Full Text] [Related]
19. A Novel Collaborative Approach to Building Better Clinical Trials: New Insights From a Patient Engagement Workshop to Propel Patient-Centricity Forward.
Gregg A; Getz N; Benger J; Anderson A
Ther Innov Regul Sci; 2020 May; 54(3):485-491. PubMed ID: 33301131
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
